Table 3.

Incidence of Tumor Growth and Regression in Athymic Mice Injected With EBV-Converted BL30 and BL41 Cell Lines

Cell Line EBV Status Tumors/ Mice InjectedDays to Tumor Appearance Days to Tumor Regression Regressing Tumors % RegressionMaximum Size (cm2)
BL30
 Parental10/10 18 ± 6.3 0/10 0.0
 P3HR-1 + 5/5 16 ± 0.0 0/5 0.0
 B95-8 + 5/5 30 ± 1173 ± 15 5/5 100 3.1 ± 1.3
 Parental + B95-8 −/+ 5/5 20 ± 0.061 ± 10 4/5 80 4.3 ± 0.6
BL41
 Parental 8/8 11 ± 4.7 0/80.0
 P3HR-1 + 10/10 17 ± 8.00/10 0.0
 B95-8 + 8/934 ± 17 68 ± 36 7/8 87 5.4 ± 2.6
 Parental + B95-8 −/+ 5/5 11 ± 5.852 ± 0.0 2/5 40 6.5 ± 3.3
  • BALB/c nu/nu mice were injected subcutaneously with 107 cells (in 0.2 mL RPMI 1640), from the indicated exponentially growing parental P3HR-1–converted or B95-8–converted BL30 or BL41 cell lines. Groups of mice were also injected with a mixture of parental EBV BL cells (BL30 or BL41 cell lines, 107 cells) and the EBV-B95-8–converted BL cells (BL30-B95-8 and BL41-B95-8, 107 cells). Experimental conditions and evaluation are described in the legend to Table 1.